Alcon Inc. (ALC) Stock

About Alcon Inc.

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Alcon Inc. is led by CEO David J. Endicott, employs 25,599 people, headquartered in Geneva, CH, publicly traded since 2019.

Alcon Inc. (ALC) stock trades at $69.11 with a market capitalization of $33.70B. The stock is valued at a price-to-earnings (P/E) ratio of 38.28, price-to-book of 1.68, price-to-sales of 2.93. Over the past 52 weeks the stock has ranged between $61.84 and $92.55, and currently trades 25.3% below its 52-week high. It pays a dividend yielding 0.44%.

On profitability, Alcon Inc. generates a return on equity (ROE) of 4.45%, return on capital employed of 6.17%, an operating margin of 13.08%, a net profit margin of 7.71%.

In its most recent fiscal year, Alcon Inc. reported annual revenue of $10.4B, net profit of $980.0M, revenue has compounded at 8.8% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.24 — a conservative balance sheet with little leverage risk, a current ratio of 2.12, total assets of $31.6B, $1.5B in cash and equivalents.

ALC has an average daily trading volume of 2,110,905.4 shares, a beta of 0.70 (less volatile than the overall market).

Official website: www.alcon.com